PMID- 9053478
OWN - NLM
STAT- MEDLINE
DCOM- 19970310
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 15
IP  - 2
DP  - 1997 Feb
TI  - Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in 
      childhood: a report from the European Working Group on Myelodysplastic Syndrome 
      in Childhood.
PG  - 566-73
AB  - PURPOSE: To evaluate the role of allogeneic bone marrow transplantation (BMT) in 
      children with chronic myelomonocytic leukemia (CMML). PATIENTS AND METHODS: 
      Forty-three children with CMML given BMT and reported to the European Working 
      Group on Myelodysplastic Syndrome in Childhood (EWOG-MDS) data base were 
      evaluated. In 25 cases, the donor was a human leukocyte antigen (HLA)-identical 
      or a one-antigen-disparate relative, in four cases a mismatched family donor, and 
      in 14 a matched unrelated donor (MUD). Conditioning regimens consisted of 
      total-body irradiation (TBI) and chemotherapy in 22 patients, whereas busulfan 
      (Bu) with other cytotoxic drugs was used in the remaining patients. RESULTS: Six 
      of 43 patients (14%), five of whom received transplants from alternative donors, 
      failed to engraft. There was a significant difference in the incidences of 
      chronic graft-versus-host disease (GVHD) between children transplanted from 
      compatible/one-antigen-mismatched relatives and from alternative donors (23% and 
      87%, respectively; P < .005). Probabilities of transplant-related mortality for 
      children given BMT from HLA-identical/one-antigen-disparate relatives or from 
      MUD/ mismatched relatives were 9% and 46%, respectively. The probability of 
      relapse for the entire group was 58%, whereas the 5-year event-free survival 
      (EFS) rate was 31%. The EFS rate for children given BMT from an HLA-identical 
      sibling or one-antigen-disparate relative was 38%. In this latter group, patients 
      who received Bu had a better EFS compared with those given TBI (62% v 11%, P < 
      .01). CONCLUSION: Children with CMML and an HLA-compatible relative should be 
      transplanted as early as possible. Improvement of donor selection, GVHD 
      prophylaxis, and supportive care are needed to ameliorate results of BMT from 
      alternative donors.
FAU - Locatelli, F
AU  - Locatelli F
AD  - Department of Pediatrics, University of Pavia, Instituto di Ricovero e Cura a 
      Carattere Scientifico Policlinico San Matteo, Italy. tmoped@ipv36.unipv.it
FAU - Niemeyer, C
AU  - Niemeyer C
FAU - Angelucci, E
AU  - Angelucci E
FAU - Bender-Gotze, C
AU  - Bender-Gotze C
FAU - Burdach, S
AU  - Burdach S
FAU - Ebell, W
AU  - Ebell W
FAU - Friedrich, W
AU  - Friedrich W
FAU - Hasle, H
AU  - Hasle H
FAU - Hermann, J
AU  - Hermann J
FAU - Jacobsen, N
AU  - Jacobsen N
FAU - Klingebiel, T
AU  - Klingebiel T
FAU - Kremens, B
AU  - Kremens B
FAU - Mann, G
AU  - Mann G
FAU - Pession, A
AU  - Pession A
FAU - Peters, C
AU  - Peters C
FAU - Schmid, H J
AU  - Schmid HJ
FAU - Stary, J
AU  - Stary J
FAU - Suttorp, M
AU  - Suttorp M
FAU - Uderzo, C
AU  - Uderzo C
FAU - van't Veer-Korthof, E T
AU  - van't Veer-Korthof ET
FAU - Vossen, J
AU  - Vossen J
FAU - Zecca, M
AU  - Zecca M
FAU - Zimmermann, M
AU  - Zimmermann M
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Bone Marrow Transplantation
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Europe
MH  - Female
MH  - Graft vs Host Disease/prevention & control
MH  - HLA Antigens
MH  - Humans
MH  - Infant
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*therapy
MH  - Male
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
AID - 10.1200/JCO.1997.15.2.566 [doi]
PST - ppublish
SO  - J Clin Oncol. 1997 Feb;15(2):566-73. doi: 10.1200/JCO.1997.15.2.566.